Market News & Trends
Certara Announces Expansion of Clinical Technology Collaboration with Merck
RADNOR, Pa., Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced a new collaboration with Merck, known as MSD outside of…
Medvantx Acquires RxS to Broaden Integrated Access & Engagement Solutions for Life Science
SAN DIEGO, Medvantx, a leading pharmacy services company, announced today that it acquired RxS, a leader in multichannel sample management and accountability solutions. The combined…
Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model
SOLANA BEACH, Calif., Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer,…
Chugai and Gero Enter into Joint Research and License Agreement to Develop Novel Therapies for Age-Related Diseases
TOKYO, Chugai Pharmaceutical Co., Ltd., and Gero PTE. LTD. , a Singapore-based biotechnology company, announced today that they have entered into a joint research and…
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
SOUTH SAN FRANCISCO, Calif., Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics…
LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada
SAN DIEGO and CLERMONT-FERRAND, France, LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Laboratoires Théa (“Théa”) announced an exclusive license and commercialization agreement for Théa to register…
Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies
Oxford, UK and San Jose, California, Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and Antibody Drug Conjugate (ADC)-based therapies,…
Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center
Vancouver, Canada, Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major…
Upperton Pharma Solutions Wins Business Expansion Award at the 2025 Pharmaceutical Technology Excellence Awards
Nottingham, UK – Upperton Pharma Solutions, a leading Nottingham-based pharmaceutical contract development and manufacturing organization (CDMO), is delighted to announce its recognition as the winner…
Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101
BOSTON, Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for…
Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement
DURHAM, N.C., Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the closing of the…
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
SAN DIEGO, - Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant…
Asahi Kasei Pharma starts Phase III study of promising CIPN prevention therapy, ART-123 (Recomodulin, to enhance treatment options worldwide
Chelmsford, MA; Novi, MI; Düsseldorf, Germany; and Tokyo, Japan - Asahi Kasei Pharma has started trial drug administration in a Phase III study of ART-123…
Aenova expands cold chain capabilities with new state-of-the-art warehouse at its sterile site in Latina
Latina (Italy), Aenova, a leading global contract development and manufacturing organization (CDMO), is investing in a new cold chain warehouse at its sterile site in…
PharmNovo announces CTA submission for lead candidate PN6047, a next generation selective Delta Opioid Receptor Agonist (DORA) for treatment of neuropathic pain
PN6047 is a first-in-class small molecule that selectively activates the delta opioid receptor (DOR), avoiding interaction with the mu opioid receptor that is the basis…
Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals
Genitourinary Tumor Study Ongoing with Active Screening and Enrollment MILAN and NEW YORK, Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced that a…
atai Life Sciences Announces $50 Million Private Placement Financing
Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1…
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli (systemic pegcetacoplan)
Apellis to receive $275 million upfront and up to $25 million in milestone payments upon EMA approval in C3G and IC-MPGN Non-dilutive financing further…
Aptamer Group Identifies Novel Target to Enable Cell-Specific Gene Therapy for Liver Fibrosis
Aptamer unveils novel biomarker for targeted liver fibrosis therapy Optimer breakthrough targets liver scarring cells, positioning Aptamer in $20bn fibrosis market Aptamer Group plc today…
Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain
First Orally Active Fatty Acid Binding Protein 5 Inhibitor Evaluated in Humans First-in-Class Approach Targets Unmet Need in Multibillion-Dollar Pain Management Market SOLANA BEACH, Calif.,…
